Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 1997

View Archived Issues

Avax evaluates its ovarian cancer vaccine in phase II

Promising preliminary phase II data reported for VX-478/141W94

PharmaPrint and AHP to collaborate on herbal products

Clinical results reported for 546C88 in septic shock

ImClone and CombiChem enter alliance for drug discovery in oncology

Schering-Plough: Q3 1997 highlights

Synthelabo: Q3 1997 highlights

Prodrugs of selective COX-2 inhibitors

Warner-Lambert prepares new cyclic amino acids related to gabapentin

BASF prepares anti-hTNF-alpha antibodies

Two large trials support use of alteplase accelerated infusion for acute MI

Shire files IND for new formulation of aciclovir

Peptech and Allergan terminate collaboration on GMDP

Cefluprenam: basic and clinical research on new injectable cephalosporin

Effects of 5-HT, TxA2 and their antagonists on restenosis

Andrx's Diltia XT approved and launched in U.S.

Alpharma will distribute PerioGlas in key European markets

FDA approves RPR's Nasacort for pediatric use

New cell therapy company to be formed by VIMRx and Baxter

Peptech reaches phase I goals for antagonist G; exercises license option

Products under development at Meiji Seika

Advisory panel to the FDA unanimously recommends PDL's Zenapax

Toyama to begin U.S. development of Alzheimer's drug

Peripheral and Central Nervous System Drugs Advisory Committee meets next month

U.S. testing of Toyama antiarthritic to begin soon

Anti-Infective Drugs Advisory Committee to discuss three NDAs

Viragen considers genital herpes as possible target for Omniferon

Australian government awards Cortecs grant for otitis media research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...